Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.60 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.60 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.52 |
| ▸ | STK4 | Q13043 | 8/20 | 0.52 |
| ▸ | STK3 | Q13188 | 8/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29804858 | 1.00 | CHEK1 (0.60) | CHEK1PDPK1MAPK1PAK1JAK3 | |
| SCHEMBL6755688 | 0.88 | HTT (0.47) | CHEK1PDPK1MAPK1PAK1JAK3 | |
| SCHEMBL29804936 | 0.84 | HTT (0.57) | CHEK1PDPK1MAPK1PAK1JAK3 | |
| SCHEMBL9095851 | 0.84 | HTT (0.57) | CHEK1PDPK1MAPK1PAK1JAK3 | |
| SCHEMBL31740761 | 0.84 | HTT (0.53) | CHEK1PDPK1MAPK1PAK1JAK3 | |
| SCHEMBL31061628 | 0.84 | CHEK1 (0.47) | CHEK1PDPK1MAPK1PAK1JAK3 | |
| SCHEMBL29804847 | 0.83 | HTT (0.58) | CHEK1PDPK1MAPK1PAK1JAK3 | |
| SCHEMBL8939237 | 0.83 | HTT (0.58) | CHEK1PDPK1MAPK1PAK1JAK3 | |
| SCHEMBL8826341 | 0.81 | IKBKB (0.52) | CHEK1PDPK1MAPK1PAK1JAK3 | |
| SCHEMBL1030418 | 0.81 | HTR2C (0.58) | CHEK1PDPK1MAPK1PAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180333420-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN | FOREVER CHEER INTERNATIONAL LTD (HK) | 2018-11-22 | — | — | US | claimed |
| EP-3403674-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN | Forever Cheer International Limited (HK) | 2018-11-21 | — | — | EP | claimed |
| US-20110098295-A1 | METHODS OF TREATING ANXIETY, ITCHING AND PSYCHIATRIC DISORDERS | ZHUO MIN | 2011-04-28 | — | — | US | claimed |
| EP-2215090-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-08-11 | — | — | EP | claimed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | claimed |
| US-12275739-B2 | Inhibitors of menin-MLL interaction | BIOMEA FUSION, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240140953-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2024-05-02 | — | — | US | disclosed |
| US-20240124467-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11845753-B2 | Inhibitors of menin-mll interaction | BIOMEA FUSION, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4263542-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | Biomea Fusion, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-0286425-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1995-01-11 | — | — | EP | disclosed |
| EP-0625158-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-23 | — | — | EP | disclosed |
| WO-1993014103-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
| US-5185437-A | 6-substituted 2',3'-dideoxypurine nucleosides; treatment for human immunodeficiency virus and heptatis b virus | BURROUGHS WELLCOME CO. (US) | 1993-02-09 | — | — | US | disclosed |
| US-5068320-A | 2-amino-6-(cyclopropylamino)purine-9-β-D-2',3'-dideoxyribofuranoside and its pharmaceutically acceptable salts | BURROUGHS WELLCOME CO. (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0421819-A1 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-10 | — | — | EP | disclosed |
| EP-0286425-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-10-12 | — | — | EP | disclosed |
| US-3996361-A | ANTIEDEMATOUS, REDUCING CAPILLARY PERMEABILITY | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275739-B2 | Inhibitors of menin-MLL interaction | MLLT1, MEN1, MLLT3 | CHEK1 1159/4885PDPK1 1267/4885MAPK1 1093/4885 |
| US-20240124467-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CHEK1 887/4885PDPK1 1206/4885MAPK1 1898/4885 |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | CHEK1 4459/4885PDPK1 2566/4885MAPK1 1351/4885 |
| US-20110098295-A1 | METHODS OF TREATING ANXIETY, ITCHING AND PSYCHIATRIC DISORDERS | SLC18A2, SLC1A2, CRH | CHEK1 4542/4885PDPK1 4496/4885MAPK1 4258/4885 |
| US-20240140953-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CHEK1 1159/4885PDPK1 1267/4885MAPK1 1093/4885 |
| US-20180333420-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN | OPRM1, OPRL1, OPRD1 | CHEK1 4715/4885PDPK1 1205/4885MAPK1 264/4885 |
| US-11845753-B2 | Inhibitors of menin-mll interaction | MLLT1, MEN1, MLLT3 | CHEK1 1159/4885PDPK1 1267/4885MAPK1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.